- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05353816
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lily Shi, VP
- Phone Number: +8613418601356
- Email: shixiaoli@coretechmed.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Fuwai Hospital, Chinese Academy of Medical Sciences(CAMS)
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Medical University Union Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital Of Central South University
-
Zhengzhou, Hunan, China
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing First Hospital
-
Suzhou, Jiangsu, China
- The First Affiliated Hospital of Soochow University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Zhongshan Hospital, Fudan University
-
-
Shanxi
-
Xi'an, Shanxi, China
- Xijing Hospital of Air Force Medical University
-
-
Xinjiang
-
Xinjiang, Xinjiang, China
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- (1) Age ≥ 18 years.
- (2) The patient or legal representative has signed the Informed Consent Form (ICF).
- (3) Body Surface Area (BSA) ≥ 1.0 m^2.
- (4) Females of childbearing age must agree to use adequate contraception.
- (5) Patients with NYHA Class IV heart failure symptoms who have failed to be reversed by previous standardized oral treatment with anti-heart failure drugs (ACEI, beta-blockers, and diuretics).
- (6) Left Ventricular Ejection Fraction (LVEF) ≤ 30%, and at least one of the following conditions occurs:
- a. Fail to be reversed by or be weaned from intra-aortic balloon pump (IABP), extracorporeal membrane oxygenator (ECMO), or other short-term mechanical circulatory support;
- b. Rely on continuous intravenous administration of one or more vasoactive or inotropic drugs;
- c. Meeting the diagnostic criteria of cardiogenic shock: blood pressure < 90/60mmHg, cardiac index < 2.0 L/min/m^2, and pulmonary capillary wedge pressure > 18mmHg.
Exclusion Criteria:
- (1) Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy pericardial disease, amyloidosis, or restrictive cardiomyopathy.
- (2) Presence of an active, uncontrolled infection confirmed by a combination of clinical symptoms and laboratory tests.
- (3) Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator.
- (4) Intolerance to anticoagulant or antiplatelet therapies or any other peri/postoperative therapy the investigator will require based on the patient's health status.
- (5) Patients require bi-ventricular assist device support.
- (6) Pregnancy.
- (7) Presence of moderate to severe aortic insufficiency or a history of the mechanical aortic valve that will not be converted to a bioprosthesis or oversewn at the time of implantation.
- (8) History of any organ transplantation.
- (9) Presence of uncorrected thrombocytopenia or severe coagulopathy, such as diffuse intravascular coagulation.
- (10) TBIL (total bilirubin) > 3.0 mg/dL, serum creatinine (SCr) > 3.0 mg/dL within 48 hours prior to LVAD implantation surgery or may require dialysis.
- (11) History of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease or a diagnosis of primary pulmonary hypertension.
- (12) Pulmonary embolism and pulmonary artery systolic blood pressure exceeding 60mmHg within 3 weeks prior to enrollment combined with at least one of the following 2 parameters demonstrating that pulmonary vascular resistance did not respond to drug therapy: Pulmonary vascular resistance greater than 8 wood units; The transpulmonary differential pressure exceeds 20mmHg.
- (13) Established and untreated abdominal or thoracic aortic aneurysm > 5cm in diameter.
- (14) Presence of severe peripheral vascular disease with resting pain or extremity ulceration.
- (15) Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and Left Ventricular Assist System management, or brain death from various causes.
- (16) Expect to live less than 1 year due to malignant tumor or other diseases.
- (17) Participation in any other clinical trials that may influence the results of this study.
- (18) Other circumstances that are unforeseen and determined by the researcher to be unsuitable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Corheart 6 LVAS
Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with end-stage heart failure.
|
Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The success rate of device implantation at 3 months.
Time Frame: Up to 3 months post-implantation.
|
The success rate of device implantation at 3 months post-implantation. Device implantation success will be met when a patient is still alive on device support, free of disabling stroke (modified Rankin Scale (mRS) > 3), and does not have the device replaced or removed due to device deficiency at 3 months post-implantation. The modified Rankin Scale is a tool used to assess functional disability or dependence in daily activities following a stroke or other neurological condition. It ranges from 0 (No observed neurological symptoms) to 6 (dead). Higher scores indicate more severe functional impairment. |
Up to 3 months post-implantation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional status as measured by the New York Heart Association (NYHA) Classification
Time Frame: Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
The NYHA (New York Heart Association) Functional Classification is a tool used to assess the severity of heart failure symptoms.
It categorizes patients into one of four classes based on their level of activity limitation and symptoms.
Class I represents no limitation of physical activity, while Class IV indicates severe limitations even at rest.
|
Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
Quality of Life as measured by the EuroQoL-5D-3L (EQ-5D-3L) questionnaire
Time Frame: Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
The EQ-5D-3L assesses health-related quality of life across five dimensions with three severity levels each.
The scores from the 5 dimensions are summed for the total score which ranges from 5 to 15 with higher scores indicating more problems and a worse quality of life.
|
Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
Quality of Life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ-23).
Time Frame: Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-3) evaluates heart failure patients' health status, including symptoms, physical limitations, social limitations, self-efficacy, and quality of life.
Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
|
Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
Functional status as measured by the Six Minute Walk Test (6MWT)
Time Frame: Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
The 6-Minute Walk Test (6MWT) assesses functional capacity and endurance by measuring the distance walked in six minutes.
Results vary based on age, gender, and disease severity.
Generally, greater distances indicate better functional capacity and endurance.
|
Baseline, at hospital discharge (assessed up to 5 days), and at 3 months post-implantation.
|
Stroke severity as assessed with the National Institutes of Health Stroke Scale (NIHSS) score.
Time Frame: From baseline to 3 months post-implantation.
|
The National Institutes of Health Stroke Scale measures stroke-related neurological deficits across various domains.
Scores range from 0 to 42, with higher scores indicating more severe neurological impairment.
Lower scores correlate with better neurological function.
|
From baseline to 3 months post-implantation.
|
Stroke severity as assessed by the modified Rankin Scale (mRS) score
Time Frame: From baseline to 3 months post-implantation.
|
The modified Rankin Scale is a tool used to assess functional disability or dependence in daily activities following a stroke or other neurological condition.
It ranges from 0 (No observed neurological symptoms) to 6 (dead).
Higher scores indicate more severe functional impairment.
|
From baseline to 3 months post-implantation.
|
Adverse Events
Time Frame: From baseline to 3 months post-implantation.
|
Frequency and incidence of all anticipated adverse events.
|
From baseline to 3 months post-implantation.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shengshou Hu, Chinese Academy of Medical Sciences, Fuwai Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COREMED_LVAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Heart Failure
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsRecruitingEnd-stage Heart FailureFrance
-
Vastra Gotaland RegionKarolinska University Hospital; University Hospital, Linkoeping; Skane University... and other collaboratorsRecruitingEnd-stage Heart FailureSweden
-
University Hospital, Strasbourg, FranceUnknownEnd-stage Heart FailureFrance
-
Heinrich-Heine University, DuesseldorfCompletedEnd Stage Heart FailureGermany
-
Medtronic Cardiac Rhythm and Heart FailureCompletedEnd-stage Heart FailureKorea, Republic of
-
Hospices Civils de LyonRecruitingEnd-stage Heart FailureFrance
-
University of AarhusNot yet recruitingEnd-stage Heart Failure
-
University of CalgaryPfizerRecruitingEnd Stage Heart FailureCanada
-
Shenzhen Core Medical Technology CO.,LTD.Completed
Clinical Trials on Corheart 6 Left Ventricular Assist System
-
Shenzhen Core Medical Technology CO.,LTD.Completed
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting
-
Shenzhen Core Medical Technology CO.,LTD.Not yet recruiting
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Abbott Medical DevicesThoratec Corporation; KCRI; Center for Life Sciences; EmergoCompletedAdvanced Refractory Left Ventricular Heart FailureGermany, Australia, Austria, Canada, Czechia, Kazakhstan
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Terumo Heart Inc.TerminatedHeart FailureUnited States, Canada
-
Central Hospital, Nancy, FranceUnknownHeart Failure | Extracorporeal Membrane Oxygenation | Cardiogenic Shock | Left Ventricular Assist DeviceFrance
-
VentracorInternational Center for Health Outcomes and Innovation ResearchUnknownCardiomyopathies | End-stage Heart FailureUnited States
-
VentracorInternational Center for Health Outcomes and Innovation ResearchUnknownCardiomyopathies | End-stage Heart FailureUnited States